| Symbol | EPHA5 |
| Full Name | Eph Receptor A5 |
| Chromosome | 5q21 |
| NCBI Gene | [1974](https://www.ncbi.nlm.nih.gov/gene/1974) |
| OMIM | [600004](https://www.omim.org/entry/600004) |
| Ensembl | [ENSG00000142347](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000142347) |
| UniProt | [P35909](https://www.uniprot.org/uniprotkb/P35909/entry) |
| Associated Diseases | [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), neurodevelopmental disorders |
EPHA5 (Eph Receptor A5) is a member of the Eph receptor tyrosine kinase family that plays crucial roles in neural development, synaptic plasticity, and cellular communication. As a receptor tyrosine kinase that binds ephrin-A ligands (particularly EFNA3 and EFNA5), EPHA5 regulates dendritic spine morphology, synaptic function, and neural circuit formation. The receptor is highly expressed in the hippocampus and cortex, brain regions critical for learning and memory that are vulnerable in neurodegenerative diseases.
The Eph-ephrin signaling system represents one of the most complex and functionally diverse receptor-ligand systems in the human genome. EPHA5 is distinguished by its high affinity for ephrin-A5, which is particularly important in hippocampal circuit formation and plasticity. Unlike other EPHA receptors, EPHA5 shows unique expression patterns in the dentate gyrus and CA3 region, suggesting specialized functions in memory consolidation.
The EPHA5 gene is located on chromosome 5q21 and spans approximately 45 kilobases, consisting of 18 exons encoding a 1035-amino acid transmembrane receptor protein. The protein structure follows the canonical Eph receptor architecture, comprising an N-terminal ephrin-binding domain, a cysteine-rich region, two fibronectin type III repeats, a transmembrane helix, and a cytoplasmic domain containing the tyrosine kinase domain.
The ephrin-binding domain of EPHA5 exhibits distinct binding characteristics, showing highest affinity for ephrin-A5, followed by ephrin-A3 and ephrin-A1. This binding specificity is determined by specific residues in the ligand-binding pocket. The receptor can also bind ephrin-B ligands through alternative splicing variants, expanding its signaling repertoire.
The cytoplasmic tyrosine kinase domain of EPHA5 contains multiple tyrosine residues that undergo autophosphorylation upon ligand binding. Key phosphorylation sites include Tyr-779, Tyr-682, and Tyr-609, which serve as docking sites for downstream signaling molecules containing SH2 domains. The kinase activity is tightly regulated by both autophosphorylation and interaction with protein tyrosine phosphatases.
EPHA5 exhibits high expression in the adult hippocampus, particularly in the CA3 region and dentate gyrus, which are critical for episodic memory and pattern completion. In the cortex, EPHA5 is prominently expressed in layer II/III and layer V pyramidal neurons, the primary excitatory neurons involved in cortical processing.
During development, EPHA5 expression is highest in the embryonic and early postnatal periods, corresponding to periods of active neurogenesis, neuronal migration, and synapse formation. The receptor is expressed in the ventricular zone and subventricular zone, where neural progenitor cells are generated, and in migrating neurons where it regulates positioning.
In the adult brain, EPHA5 continues to be expressed in neurogenic niches, including the subgranular zone of the dentate gyrus and the subventricular zone. This expression suggests roles in adult neurogenesis and neural plasticity throughout life.
The Eph-ephrin system plays a fundamental role in regulating synaptic plasticity, the cellular basis of learning and memory. EPHA5 contributes to synaptic plasticity through multiple mechanisms, including regulation of dendritic spine morphology, modulation of glutamatergic synaptic transmission, and influence on long-term potentiation (LTP) and long-term depression (LTD) (Lu et al., 2019).
Dendritic spines are small actin-rich protrusions from dendritic shafts that receive the majority of excitatory synaptic inputs. EPHA5 signaling regulates spine morphogenesis through modulation of the actin cytoskeleton. Upon ephrin-A5 binding, EPHA5 activates downstream effectors such as Vav2/3 and RacGAP1, which regulate Rac1 and Cdc42 activity. This signaling cascade controls the formation, maintenance, and plasticity of dendritic spines (Yang et al., 2019).
Studies have demonstrated that EPHA5 localizes to both presynaptic and postsynaptic compartments. At the postsynaptic density, EPHA5 interacts with NMDA receptor subunits and influences NMDA receptor-mediated calcium influx, a critical signal for LTP induction (Li et al., 2019). EPHA5 also modulates AMPA receptor trafficking, influencing synaptic strength and connectivity.
Multiple lines of evidence implicate EPHA5 in the pathogenesis of Alzheimer's disease, particularly in hippocampal dysfunction and memory impairment (Rosendahl et al., 2018).
The amyloid cascade hypothesis posits that accumulation of Aβ peptides initiates neurodegeneration. EPHA5 has been shown to interact with the amyloid precursor protein (APP) processing machinery. Studies demonstrate that Aβ oligomers disrupt normal EPHA5 signaling, contributing to synaptic dysfunction (Zhang et al., 2021).
EPHA5 expression is altered in AD brains, with decreased levels in the hippocampus correlating with cognitive decline. This downregulation may contribute to the synaptic loss that characterizes AD.
Tau protein hyperphosphorylation represents a hallmark of AD. EPHA5 signaling interacts with tau pathology through modulation of kinase and phosphatase activities. Hyperphosphorylated tau can disrupt EPHA5 receptor trafficking and signaling at synapses (Fan et al., 2019).
EPHA5 plays a crucial role in maintaining synaptic integrity. The receptor regulates the function of both glutamatergic and GABAergic synapses. At glutamatergic synapses, EPHA5 modulates NMDA receptor function and trafficking, affecting calcium signaling essential for synaptic plasticity. Loss of EPHA5 function in AD leads to impaired LTP and disrupted synaptic plasticity necessary for learning and memory.
Neuroinflammation is a hallmark of AD. EPHA5 is expressed in glial cells and modulates neuroinflammatory responses. The role is complex and context-dependent, with acute activation potentially promoting anti-inflammatory responses while chronic activation may contribute to neurotoxic microglial phenotypes.
EPHA5 has been implicated in Parkinson's disease through its effects on dopaminergic neuron survival and basal ganglia plasticity (Wang et al., 2020).
The Eph-ephrin system plays important roles in dopaminergic neuron development and survival. EPHA5 activation by ephrin-A5 promotes nigrostriatal dopamine neuron survival through PI3K/Akt signaling pathways (Zhao et al., 2018). Dysregulation of this signaling may contribute to PD progression.
EPHA5 is expressed in the striatum and modulates synaptic plasticity in basal ganglia circuits. This plasticity is essential for motor learning and habit formation, which are disrupted in PD.
During development, EPHA5 guides neuronal migration and axon pathfinding through contact-dependent repulsion. The receptor interacts with ephrin-A ligands expressed on neighboring cells, creating repulsive cues that shape neural circuit formation.
EPHA5 is particularly important in hippocampal development, where it regulates the migration of granule cells from the dentate gyrus neurogenic niche. The receptor also plays a role in cortical development, regulating the layering of cortical neurons.
In the adult brain, EPHA5 continues to play important roles in adult neurogenesis in the hippocampus (Tian et al., 2021). New neurons generated in the dentate gyrus integrate into hippocampal circuits, a process that is important for memory and is impaired in AD.
Upon ephrin-A5 binding, EPHA5 triggers multiple downstream signaling cascades that mediate its diverse cellular functions:
RAS/MAPK Pathway: EPHA5 activation recruits GRB2 and SOS, leading to activation of RAS and subsequently RAF-MEK-ERK. This pathway is critical for neuronal differentiation, survival, and synaptic plasticity. ERK activation in neurons regulates transcription factors involved in memory formation, including CREB.
PI3K/AKT Pathway: EPHA5 activates PI3K, leading to AKT phosphorylation. This pathway promotes cell survival and protects neurons from apoptotic cell death. AKT signaling also regulates synaptic plasticity by modulating ion channel function and neurotransmitter receptor trafficking.
Rho GTPase Pathways: EPHA5 signaling modulates Rho GTPase activity through Vav family GEFs and RacGAP1. Rac1 and Cdc42 regulate actin cytoskeleton dynamics, controlling dendritic spine formation and morphology. RhoA signaling influences contractile processes and spine retraction.
PLCγ Pathway: EPHA5 activation stimulates PLCγ, leading to IP3 production and calcium release. This pathway modulates synaptic transmission and gene expression. Calcium signaling through PLCγ is important for activity-dependent plasticity.
Like other Eph receptors, EPHA5 can mediate reverse signaling through its ephrin ligands. When EPHA5 on one cell engages ephrin-A5 on a neighboring cell, the ephrin molecule can signal back into the ephrin-expressing cell. This bidirectional signaling enables complex cell-cell communication during development and in the adult brain.
The hippocampus shows the highest EPHA5 expression in the adult brain. In the CA3 region, EPHA5 is expressed in pyramidal neurons where it regulates synaptic plasticity and memory consolidation. The receptor is particularly important for pattern separation and completion, cognitive processes mediated by the trisynaptic circuit.
In the dentate gyrus, EPHA5 is expressed in granule cells and hilar interneurons. The receptor regulates adult neurogenesis through effects on neural progenitor cell proliferation, differentiation, and survival. Newborn neurons that integrate into hippocampal circuits rely on EPHA5 signaling for proper synaptic connectivity.
In the cortex, EPHA5 is enriched in layer II/III and layer V pyramidal neurons. These neurons project to other cortical regions and subcortical structures, forming corticocortical and corticospinal circuits. EPHA5 in these neurons regulates synaptic plasticity and information processing.
EPHA5 is also expressed in cortical interneurons, where it modulates inhibitory synaptic transmission. The balance of excitation and inhibition in cortical circuits is critical for proper brain function, and EPHA5 contributes to maintaining this balance.
In the basal ganglia, EPHA5 is expressed in the striatum and substantia nigra. The receptor modulates dopaminergic signaling and regulates synaptic plasticity in striatal medium spiny neurons. These neurons are the primary output of the striatum and are affected in Parkinson's disease.
EPHA5 is expressed in the olfactory bulb, where it participates in olfactory circuit formation and plasticity. The olfactory system continues to generate new neurons throughout life, and EPHA5 may regulate this neurogenesis.
Several EPHA5 mutations have been identified in patients with neurodevelopmental disorders. These mutations often affect the kinase domain or ligand-binding domain, leading to altered receptor function.
Missense mutations in EPHA5 have been associated with:
These mutations may cause either loss-of-function or gain-of-function, with different consequences for neural development and circuit formation.
Genetic polymorphisms in EPHA5 have been associated with susceptibility to Alzheimer's disease and Parkinson's disease. These variants may affect receptor expression levels or signaling efficiency, modulating disease risk.
EPHA5 shares structural and functional similarities with other EPHA receptors, but has distinct characteristics:
The specific ligand-binding preferences and expression patterns of EPHA5 make it uniquely suited for its roles in hippocampal function and neurodegenerative disease.
Research on EPHA5 utilizes multiple model systems:
Understanding EPHA5 function in neurodegenerative disease will require:
Given its central role in synaptic plasticity and neurodegeneration, EPHA5 represents a promising therapeutic target:
EPHA5 agonists: Small molecule or peptide agonists that enhance EPHA5 signaling may promote synaptic plasticity and neuroprotection (Sun et al., 2020)
Gene therapy: Viral vectors delivering functional EPHA5 may restore normal signaling
Biomarkers: EPHA5 expression levels in CSF or blood may serve as biomarkers for disease progression (Hu et al., 2021)
Combination therapies: Targeting EPHA5 alongside other disease mechanisms may provide synergistic benefits
EPHA5 knockout mice show significant memory deficits in hippocampal-dependent learning tasks (Huang et al., 2020). These mice have reduced dendritic spine density in the hippocampus and impaired LTP.
Transgenic mice overexpressing EPHA5 show enhanced hippocampal plasticity and improved memory performance, providing evidence for the receptor's role in cognitive function.
EPHA5 interacts with numerous proteins to mediate its signaling effects: